Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Cash from Investing Activities: 2019-2024

Historic Cash from Investing Activities for Relay Therapeutics (RLAY) over the last 6 years, with Dec 2024 value amounting to -$41.1 million.

  • Relay Therapeutics' Cash from Investing Activities rose 131.49% to $39.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $186.3 million, marking a year-over-year increase of 1891.16%. This contributed to the annual value of -$41.1 million for FY2024, which is 115.95% down from last year.
  • Relay Therapeutics' Cash from Investing Activities amounted to -$41.1 million in FY2024, which was down 115.95% from $257.6 million recorded in FY2023.
  • Over the past 5 years, Relay Therapeutics' Cash from Investing Activities peaked at $257.6 million during FY2023, and registered a low of -$479.5 million during FY2021.
  • Over the past 3 years, Relay Therapeutics' median Cash from Investing Activities value was -$41.1 million (recorded in 2024), while the average stood at $9.3 million.
  • As far as peak fluctuations go, Relay Therapeutics' Cash from Investing Activities tumbled by 687.12% in 2021, and later soared by 236.50% in 2023.
  • Yearly analysis of 5 years shows Relay Therapeutics' Cash from Investing Activities stood at $81.7 million in 2020, then tumbled by 687.12% to -$479.5 million in 2021, then soared by 60.64% to -$188.7 million in 2022, then spiked by 236.50% to $257.6 million in 2023, then crashed by 115.95% to -$41.1 million in 2024.